# Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma

> **NCT01282463** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 148 (actual)

## Conditions studied

- Carcinoma of Urinary Tract
- Urethral Carcinoma
- Carcinoma of Ureter
- Carcinoma of Renal Pelvis

## Interventions

- **DRUG:** Docetaxel
- **BIOLOGICAL:** Ramucirumab DP
- **BIOLOGICAL:** Icrucumab

## Key facts

- **NCT ID:** NCT01282463
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2015-02
- **Final completion:** 2015-03
- **Target enrollment:** 148 (ACTUAL)
- **Last updated:** 2019-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01282463

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01282463, "Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01282463. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*